Search
Cardiolipin Biosynthesis CL(a-15:0/i-19:0/i-20:0/a-21:0)
smpdb.ca/view/SMP0470208MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(a-15:0/i-20:0/a-21:0/i-21:0)
smpdb.ca/view/SMP0478394MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(a-15:0/i-20:0/i-21:0/a-25:0)
smpdb.ca/view/SMP0478467MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(a-15:0/i-20:0/i-24:0/a-25:0)
smpdb.ca/view/SMP0478517MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-14:0/i-20:0/a-21:0/a-25:0)
smpdb.ca/view/SMP0480080MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-15:0/i-20:0/a-21:0/a-21:0)
smpdb.ca/view/SMP0480456MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(i-15:0/i-20:0/a-25:0/a-25:0)
smpdb.ca/view/SMP0480478MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor. … Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
ATP-dependent 6-phosphofructokinase, muscle type
go.drugbank.com/bio_entities/BE0012586TargetHumansCatalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis
Synonyms: PFK-A, 6-phosphofructokinase type AVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalVoxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) … Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible
Mixtures: VOSEVİ 400 MG/ 100 MG/ 100 MG FİLM KAPLI TABLET, 28 ADETCategories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsPhenylpropanolamine
go.drugbank.com/drugs/DB00397ApprovedVet approvedWithdrawnPhenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. … It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Mixtures: PAROL COLD 325 MG KAPSUL, 20 ADET, GLİFENTOL ŞURUP, 150 MLCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Adrenergic beta-2 Receptor Agonists